BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Epitomee® Successfully Completes Pivotal Trial for Innovative Weight Loss Capsule

The primary objective of the RESET trial was to collect data to support a planned FDA regulatory submission, paving the way for the marketing and distribut...

January 17, 2024 | News

CARsgen's CT011 Granted NMPA IND Clearance for GPC3-Positive Stage Ⅲa Liver Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

January 16, 2024 | News

Australia Achieves Positive Results in Phase Ib Study for Androgenic Alopecia Treatment

This study is led by Professor Rodney Sinclair and included 12 male and 4 female patients in Australia with androgenic alopecia (AGA). ...

January 15, 2024 | News

Renovion Finishes Adult Patient Enrollment in Phase 2 CLIMB Study for Bronchiectasis

CLIMB is a US based, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability and efficacy of ARINA-1 in participant...

January 12, 2024 | News

Teva Completes Recruitment for Phase 3 Study of MedinCell's mdc-TJK/Olanzapine LAI

mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. ...

January 11, 2024 | News

Medidata Tops Everest Group's Decentralized Clinical Trial Platforms PEAK Matrix®

-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, has again been recognized as ...

January 10, 2024 | News

Menarini Silicon Biosystems Publishes DETECT III Trial Results on HER2 Testing in Circulating Tumor Cells with CELLSEARCH

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of the fina...

January 10, 2024 | News

GC Cell Initiates Phase 1 Trials for AB-201 Cancer Treatment with Lunit AI Platform

GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) a...

January 09, 2024 | News

OBI Pharma's partner Biosion announces FDA clearance for the Phase 1/2 study of OBI-992 (TROP2 ADC)

First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...

January 09, 2024 | News

Caliway's CBL-514 IND for Dercum's Disease Phase 2 Study Accepted by FDA

Dercum's disease is a rare disease characterized by the growth of painful lipomas. The pain can be severe, chronic (> 3 months) and often disabling. So ...

January 09, 2024 | News

Suvoda Achieves 30% Growth in 2023 with Successful Platform and Product Adoption

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system...

January 08, 2024 | News

Akeso's Cadonilimab Granted NMPA Acceptance for First-Line Gastric Cancer Treatment.

This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...

January 08, 2024 | News

Belief BioMed Completes First Dosing in Hemophilia A Trial

BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...

January 04, 2024 | News

Sciwind Biosciences Reports Positive Phase 3 Results for Ecnoglutide in Chinese Type 2 Diabetes Trial

Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, ...

January 03, 2024 | News

Stay Connected